Dual Targeting Strategy: Colchicine and Paclitaxel Combination Against Prostate Cancer Cells Colchicine-Paclitaxel Synergy in Prostate Cancer

Objective: Prostate cancer is the leading male malignancy. Despite therapeutic advances, drug resistance remains a major obstacle, leading many patients to develop castration-resistant prostate cancer. This study investigates the combined effects of the microtubule-targeting agents colchicine and paclitaxel on DU145 prostate cancer cells. Methods: scratch assay, and acridine orange/ethidium bromide staining. Results: , the combined treatment nearly abolished colony formation and significantly increased apoptotic and necrotic morphology. These findings reveal that combining sub-therapeutic doses effectively inhibits cell viability, long-term proliferation, and cell motility, where monotherapies are insufficient. Conclusions: ), and effectively suppresses DU145 prostate cancer cell progression. This dual microtubule-targeting approach may overcome the limitations of monotherapy by significantly inhibiting cell motility and clonogenic survival, while enhancing apoptotic and necrotic cell morphology. Our results suggest that low-dose combination strategies may provide high therapeutic efficacy while minimizing systemic toxicity in the management of advanced prostate cancer.